Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta‐analysis

Published:2021-06-03 Issue:6 Volume:36 Page:
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum Psychopharmacol Clin Exp

Author:

Zangani Caroline¹²³⁴^ORCID,Giordano Barbara⁴^ORCID,Stein Hans‐Christian⁴^ORCID,Bonora Stefano⁴,D'Agostino Armando⁴^ORCID,Ostinelli Edoardo Giuseppe¹²³^ORCID

Affiliation:

1. Oxford Health NHS Foundation Trust, Warneford Hospital Oxford UK

2. Department of Psychiatry University of Oxford Oxford UK

3. Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre Oxford UK

4. Department of Health Sciences University of Milan Milan Italy

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hup.2801

Reference63 articles.

1. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

2. Treatment-resistant depression: therapeutic trends, challenges, and future directions

3. Diagnostic and Statistical Manual of Mental Disorders

4. Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study

5. Depressive spectrum diagnoses

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial;Journal of Psychiatric Research;2024-05

2. Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study;Drugs & Therapy Perspectives;2024-03

3. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia;Expert Review of Clinical Pharmacology;2023-10-27

4. New Pharmacologic Approaches to the Treatment of Bipolar Depression;Drugs;2023-05-25

5. Prepandemic psychotropic drug status in Portugal: a nationwide pharmacoepidemiological profile;Scientific Reports;2023-04-27